Axitinib (BioDeep_00000398804)
natural product
代谢物信息卡片
Axitinib
化学式: C22H18N4OS (386.1201258)
中文名称: 阿西替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1(=CC=CC=C1C(=O)NC)SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
InChI: InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EK - Vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
数据库引用编号
11 个数据库交叉引用编号
- ChEBI: CHEBI:94568
- ChEBI: CHEBI:66910
- KEGGdrug: D03218
- PubChem: 6450551
- Metlin: METLIN85189
- DrugBank: DB06626
- ChEMBL: CHEMBL1289926
- MeSH: Axitinib
- CAS: 1528729-60-3
- CAS: 319460-85-0
- MoNA: CCMSLIB00000077994
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xianhua She, Donghong Yin, Qian Guo, Yang Tang, Shuyun Wang, Xuyan Wang. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
Scientific reports.
2024 03; 14(1):5592. doi:
10.1038/s41598-024-56335-4. [PMID: 38454105] - Lele Ling, Bingrong Li, Huijing Wu, Kaiyong Zhang, Siwen Li, Boliang Ke, Zhengyang Zhu, Te Liu, Peng Liu, Bimeng Zhang. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
The journal of gene medicine.
2024 Jan; 26(1):e3606. doi:
10.1002/jgm.3606. [PMID: 38282157] - Weimin Zhong, Huijing Chen, Jiayi Yang, Chaoqun Huang, Yao Lin, Jiyi Huang. Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology.
BMC medical genomics.
2023 10; 16(1):265. doi:
10.1186/s12920-023-01687-5. [PMID: 37885006] - Hao Jiang, Jian Liao, Liezhi Wang, Chong Jin, Jinggang Mo, Sheng Xiang. The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms.
Frontiers in immunology.
2023; 14(?):1163967. doi:
10.3389/fimmu.2023.1163967. [PMID: 37325670] - Qiong Fang, Zhiying Li, Ye Xue, Xin Zong, Wenshuang Ma, Guangmin Xi, XiaoFeng Zhang, Zuowei Li. Embelin enhances the sensitivity of renal cancer cells to axitinib by inhibiting HIF signaling pathway.
Anti-cancer agents in medicinal chemistry.
2022 Aug; ?(?):. doi:
10.2174/1871520622666220825155125. [PMID: 36028958] - Victor Gaillard, Albane Lhuillier, Cécile Bigot, Laure Pierard, Philippe Trensz, Mickael Burgy, Caroline Schuster, Gabriel Malouf, Aurélie Fritsch, Hervé Lang, Thibault Tricard, Delphine Borchiellini, Lionnel Geoffrois, Philippe Barthelemy. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2022 Aug; 30(8):6583-6591. doi:
10.1007/s00520-022-07088-1. [PMID: 35484315] - Umberto Capitanio, Giuseppe Fallara, Daniele Raggi, Luigi Nocera, Alessandro Larcher, Federico Belladelli, Isaline Rowe, Alberto Briganti, Andrea Salonia, Pierre Karakiewicz, Francesco Montorsi, Alberto Martini, Andrea Necchi. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
Current problems in cancer.
2022 Aug; 46(4):100875. doi:
10.1016/j.currproblcancer.2022.100875. [PMID: 35679628] - Li Zhou, Yiqiang Liu, Jiazhi Mo, Chuanliang Cui, Zhihong Chi, Lu Si, Yan Kong, Xieqiao Yan, Siming Li, Xiaowen Wu, Juan Li, Huayan Xu, Dengfeng Cao, Jun Guo, Xinan Sheng. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.
Urologic oncology.
2022 Aug; 40(8):385.e1-385.e8. doi:
10.1016/j.urolonc.2022.05.014. [PMID: 35773144] - Di Zhang, Qian Li, Xiangwu Chen, Xinxin Nie, Fumin Xue, Wei Xu, Yuxia Luan. An Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy.
Small (Weinheim an der Bergstrasse, Germany).
2022 08; 18(32):e2202663. doi:
10.1002/smll.202202663. [PMID: 35843879] - Hyerim Ha, Jin Hyoung Kang, Do Yeun Kim, Seung Jin Bae, Hee Yeon Lee. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
BMC health services research.
2022 Jul; 22(1):900. doi:
10.1186/s12913-022-08279-6. [PMID: 35821026] - Irbaz Bin Riaz, Qurat Ul Ain Riaz Sipra, Syed Arsalan Ahmed Naqvi, Huan He, Rabbia Siddiqi, Mahnoor Islam, Noureen Asghar, Waleed Ikram, Wenxin Xu, Hongfong Liu, Parminder Singh, Thai Huu Ho, Mehmet Asim Bilen, Yousef Zakharia, Alan Haruo Bryce, Mohammad Hassan Murad. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis.
Critical reviews in oncology/hematology.
2022 Jul; 175(?):103706. doi:
10.1016/j.critrevonc.2022.103706. [PMID: 35537621] - Ryo Fujiwara, Susumu Kageyama, Takeshi Yuasa. Developments in personalized therapy for metastatic renal cell carcinoma.
Expert review of anticancer therapy.
2022 Jun; 22(6):647-655. doi:
10.1080/14737140.2022.2075347. [PMID: 35531636] - Kevin Neuzil, Kathryn Gessner, John Hedgepeth, Sara E Wobker, Eric M Wallen, Katherine P Morgan, Marc A Bjurlin, Tracy L Rose. Complete Pathologic Response to Pembrolizumab and Axitinib in a Patient With Sarcomatoid RCC and Ocrelizumab-Treated Multiple Sclerosis.
Urology.
2022 Jun; 164(?):50-54. doi:
10.1016/j.urology.2021.12.015. [PMID: 34973243] - Aaron R Lim, Benjamin G Vincent, Alissa M Weaver, W Kimryn Rathmell. Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma.
Cancer gene therapy.
2022 Jun; 29(6):683-696. doi:
10.1038/s41417-021-00345-1. [PMID: 34088993] - Hiroaki Ikesue, Kenta Yamaoka, Ayako Matsumoto, Masaki Hirabatake, Nobuyuki Muroi, Toshinari Yamasaki, Mutsushi Kawakita, Tohru Hashida. Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.
Cancer chemotherapy and pharmacology.
2022 Jun; 89(6):833-838. doi:
10.1007/s00280-022-04408-4. [PMID: 35254504] - Jiwei Huang, Guohai Shi, Yueming Wang, Ping Wang, Jin Zhang, Wen Kong, Yiran Huang, Shuo Wang, Wei Xue. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study.
Future oncology (London, England).
2022 Apr; 18(12):1461-1471. doi:
10.2217/fon-2021-1267. [PMID: 35103528] - Brian I Rini, Michael B Atkins, Elizabeth R Plimack, Denis Soulières, Raymond S McDermott, Jens Bedke, Sophie Tartas, Boris Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, Przemyslaw Langiewicz, Lori A Wood, Hans Hammers, Cynthia G Silber, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
European urology oncology.
2022 04; 5(2):225-234. doi:
10.1016/j.euo.2021.05.007. [PMID: 34244116] - Joanna C Masters, Akash Khandelwal, Alessandra di Pietro, Haiqing Dai, Satjit Brar. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
CPT: pharmacometrics & systems pharmacology.
2022 04; 11(4):458-468. doi:
10.1002/psp4.12771. [PMID: 35166465] - Y Tomita, R J Motzer, T K Choueiri, B I Rini, H Miyake, H Uemura, L Albiges, Y Fujii, Y Umeyama, J Wang, M Mariani, M Schmidinger. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
ESMO open.
2022 04; 7(2):100450. doi:
10.1016/j.esmoop.2022.100450. [PMID: 35397432] - Tomohiro Kanaki, Ryo Tanaka, Yasutomo Nakai, Akinaru Yamamoto, Yoshiyuki Yamamoto, Akira Nagahara, Masashi Nakayama, Kenichi Kakimoto, Kazuo Nishimura. [A Case of Pleural Empyema with Fistula Caused by Endobronchial Metastasis of Renal Cell Carcinoma].
Hinyokika kiyo. Acta urologica Japonica.
2022 Apr; 68(4):113-116. doi:
10.14989/actauroljap_68_4_113. [PMID: 35613899] - Shuchi Gulati, Chris Labaki, Georgia Sofia Karachaliou, Toni K Choueiri, Tian Zhang. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.
The oncologist.
2022 03; 27(2):125-134. doi:
10.1093/oncolo/oyab056. [PMID: 35641205] - Mehmet A Bilen, Brian I Rini, Martin H Voss, James Larkin, John B A G Haanen, Laurence Albiges, Lance C Pagliaro, Eric G Voog, Elaine T Lam, Nikolay Kislov, Bradley A McGregor, Aly-Khan A Lalani, Bo Huang, Alessandra di Pietro, Stan Krulewicz, Paul B Robbins, Toni K Choueiri. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 02; 28(4):738-747. doi:
10.1158/1078-0432.ccr-21-1688. [PMID: 34789480] - Luigi Cerbone, Vincenzo Di Nunno, Lucia Carril Ajuria, Carolina Alves Costa Silva, Emeline Colomba, Annalisa Guida, Flore Salviat, Laure Hirsch, Axelle Benchimol-Zouari, Ronan Flippot, Bernard Escudier, Laurence Albiges. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
Clinical genitourinary cancer.
2022 02; 20(1):80-87. doi:
10.1016/j.clgc.2021.09.001. [PMID: 34688544] - Arman Alimohammadi, Harun Fajkovic, Mesut Remzi, Shahrokh Shariat, Manuela Schmidinger. Recent pharmacological approaches for the treatment of renal cell carcinoma.
Expert review of clinical pharmacology.
2022 Feb; 15(2):187-195. doi:
10.1080/17512433.2022.2053521. [PMID: 35285369] - Álvaro Pinto, Oscar Reig, Clara Iglesias, Enrique Gallardo, Xavier García-Del Muro, Teresa Alonso, Georgia Anguera, Cristina Suárez, José Muñoz-Langa, Laura Villalobos-León, Ángel Rodríguez-Sánchez, Nuria Lainez, Esther Martínez-Ortega, Marc Campayo, Alejandro Velastegui, Alejo Rodriguez-Vida, José C Villa-Guzmán, Maria J Méndez-Vidal, Gustavo Rubio, Iciar García, Laia Capdevila, Julio Lambea, Sergio Vázquez, Ovidio Fernández, Susana Hernando-Polo, Sara Cerezo, Carmen Santander, Rosa García-Marrero, Francisco Zambrana, Aranzazu González-Del Alba, Martin Lazaro-Quintela, Daniel Castellano, Isabel Chirivella, Urbano Anido, Antonio Viana, Arancha García, Miguel Sotelo, María Garrido Arévalo, Jesús García-Donas, Carolina Hernández, M Victoria Bolós, Julia Llinares, Miguel A Climent. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Clinical genitourinary cancer.
2022 02; 20(1):25-34. doi:
10.1016/j.clgc.2021.09.006. [PMID: 34789409] - Alan Chan, Carolyn Dang, Jessica Wisniewski, Xiuhua Weng, Edward Hynson, Lixian Zhong, Leslie Wilson. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
American journal of clinical oncology.
2022 02; 45(2):66-73. doi:
10.1097/coc.0000000000000884. [PMID: 34991104] - L Zhou, H Y Xu, X Q Yan, S M Li, Z H Chi, L Si, Z L Cui, J Li, X W Wu, J Guo, X N Sheng. [Preliminary effects of toripalimab combined with axitinib in the treatment of advanced renal cell carcinoma].
Zhonghua yi xue za zhi.
2022 Jan; 102(2):136-140. doi:
10.3760/cma.j.cn112137-20210527-01225. [PMID: 35012303] - Bo-Wen Zhang, Ni-Hong Pang, Ren-Ai Xu, Gao-Er Qu, Cong-Rong Tang. Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo.
Drug design, development and therapy.
2022; 16(?):2031-2042. doi:
10.2147/dddt.s359451. [PMID: 35795848] - Viktor Grünwald, Thomas Hilser, Johannes Meiler, Peter J Goebell, Philipp Ivanyi, Arne Strauss, Arndt Hartmann, Jens Bedke, Lothar Bergmann. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Oncology research and treatment.
2022; 45(5):272-280. doi:
10.1159/000522043. [PMID: 35045416] - Satoshi Tamada, Chihiro Kondoh, Nobuaki Matsubara, Ryuichi Mizuno, Go Kimura, Satoshi Anai, Yoshihiko Tomita, Masafumi Oyama, Naoya Masumori, Takahiro Kojima, Hiroaki Matsumoto, Mei Chen, Mengran Li, Kenji Matsuda, Yoshinobu Tanaka, Brian I Rini, Hirotsugu Uemura. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
International journal of clinical oncology.
2022 Jan; 27(1):154-164. doi:
10.1007/s10147-021-02014-7. [PMID: 34800178] - Matteo Santoni, Alessandro Rizzo, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Benedetta Fragomeno, Nicola Battelli, Francesco Massari. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Expert review of pharmacoeconomics & outcomes research.
2022 Jan; 22(1):45-51. doi:
10.1080/14737167.2021.1937130. [PMID: 34058953] - Reshma Ramachandran, Christopher J Morten, Joseph S Ross. Strengthening the FDA's Enforcement of ClinicalTrials.gov Reporting Requirements.
JAMA.
2021 Dec; 326(21):2131-2132. doi:
10.1001/jama.2021.19773. [PMID: 34766971] - Hajime Sasagawa, Kazuyuki Numakura, Gaku Nakamura, Takashi Kukimoto, Akane Kikuchi, Ryuichiro Sagehashi, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Shigeru Satoh, Tomonori Habuchi. [Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report].
Hinyokika kiyo. Acta urologica Japonica.
2021 Dec; 67(12):525-528. doi:
10.14989/actauroljap_67_12_525. [PMID: 34991292] - Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H Giles, Milan Hora, Thomas B Lam, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
European urology.
2021 10; 80(4):393-397. doi:
10.1016/j.eururo.2021.04.042. [PMID: 34074559] - Jiwei Huang, Yueming Wang, Haoran Zhang, Xiaoyi Hu, Ping Wang, Wen Cai, Yichu Yuan, Hao Zeng, Jin Zhang, Wen Kong, Yiran Huang, Shuo Wang, Jianming Guo, Qiang Wei, Wei Xue. Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.
Cancer communications (London, England).
2021 10; 41(10):1071-1074. doi:
10.1002/cac2.12206. [PMID: 34363742] - Ahmet Cetinkaya, S Irem Kaya, Goksu Ozcelikay, Esen Bellur Atici, Sibel A Ozkan. A molecularly imprinted electrochemical sensor based on highly selective and an ultra-trace assay of anti-cancer drug axitinib in its dosage form and biological samples.
Talanta.
2021 Oct; 233(?):122569. doi:
10.1016/j.talanta.2021.122569. [PMID: 34215065] - Sota Inaba, Takeshi Sasaki, Yuna Hattori, Takashi Terabe, Momoko Kato, Shinichiro Higashi, Manabu Kato, Satoru Masui, Yuko Yoshio, Kouhei Nishikawa, Aoi Hayasaki, Takashi Yamanaka, Katsunori Uchida, Takahiro Inoue. [Presurgical Treatment with Axitinib and Pembrolizumab Reduced Operation Risk by Downsizing the Vena Cava Tumor Thrombus in Clear Cell Renal Cell Carcinoma : A Case Report].
Hinyokika kiyo. Acta urologica Japonica.
2021 Oct; 67(10):443-447. doi:
10.14989/actauroljap_67_10_443. [PMID: 34742168] - Brian I Rini, Michael B Atkins, Toni K Choueiri, Despina Thomaidou, Brad Rosbrook, Maghull Thakur, Thomas E Hutson. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma.
Clinical genitourinary cancer.
2021 10; 19(5):e306-e312. doi:
10.1016/j.clgc.2021.03.019. [PMID: 33947608] - Eun Joo Kang, Myung-Ju Ahn, Chan-Young Ock, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Byung-Ho Nam, Sung-Bae Kim, Bhumsuk Keam. Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 10; 27(19):5272-5279. doi:
10.1158/1078-0432.ccr-21-1061. [PMID: 34315722] - Hoon Yu, Dong-Jin Kim, Hye-Young Choi, So Myoung Kim, Md Intazur Rahaman, Young-Hoon Kim, So Won Kim. Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines.
BMC cancer.
2021 Sep; 21(1):1049. doi:
10.1186/s12885-021-08784-7. [PMID: 34560848] - Oktay Halit Aktepe, Fadime Sinem Ardic, Deniz Yuce, Deniz Can Guven, Gurkan Guner, Hasan Cagri Yildirim, Saadettin Kilickap, Alev Turker, Neyran Kertmen, Serkan Akin, Sercan Aksoy, Omer Dizdar, Suayib Yalcin, Mustafa Erman. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
2021 Sep; 26(5):2067-2073. doi:
NULL. [PMID: 34761618] - Kazuyuki Numakura, Yumin Muto, Sei Naito, Shingo Hatakeyama, Renpei Kato, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Syuya Kandori, Sadafumi Kawamura, Yoichi Arai, Akihiro Ito, Hiroyuki Nishiyama, Yoshiyuki Kojima, Wataru Obara, Chikara Ohyama, Norihiko Tsuchiya, Tomonori Habuchi. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
Cancer medicine.
2021 09; 10(17):5839-5846. doi:
10.1002/cam4.4130. [PMID: 34313025] - Rebecca Shay, Andrew Nicklawsky, Dexiang Gao, Elaine T Lam. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.
Clinical genitourinary cancer.
2021 08; 19(4):370-370.e7. doi:
10.1016/j.clgc.2021.01.009. [PMID: 33674224] - Fahad Quhal, Keiichiro Mori, Mesut Remzi, Harun Fajkovic, Shahrokh F Shariat, Manuela Schmidinger. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis.
Current opinion in urology.
2021 07; 31(4):332-339. doi:
10.1097/mou.0000000000000889. [PMID: 33965978] - Toni K Choueiri, Yousef Zakharia, Sumanta Pal, Judit Kocsis, Russell Pachynski, Alexandr Poprach, Andrew B Nixon, Yingmiao Liu, Mark Starr, Jing Lyu, Kouros Owzar, Mollie deShazo, Primo Lara, Lajos Geczi, Thai H Ho, Meghara Walsh, Bonne Adams, Liz Robertson, Mohamed Darif, Charles Theuer, Neeraj Agarwal. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
The oncologist.
2021 07; 26(7):560-e1103. doi:
10.1002/onco.13777. [PMID: 33829609] - Kaoru Ito, Hiroki Takamori, Takahiro Akioka, Takuya Hida, Ko Okabe, Kazutaka Kida, Naoki Terada, Toshio Kamimura, Shoichiro Mukai, Toshiyuki Kamoto. [A Case of Stauffer Syndrome-Like Findings Associated with Metastatic Renal Cell Cancer Improved by Molecular Targeted Therapy].
Hinyokika kiyo. Acta urologica Japonica.
2021 Jul; 67(7):309-312. doi:
10.14989/actauroljap_67_7_309. [PMID: 34353011] - Martina Spisarová, Bohuslav Melichar, Denisa Vitásková, Hana Študentová. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Expert review of anticancer therapy.
2021 07; 21(7):693-703. doi:
10.1080/14737140.2021.1903321. [PMID: 33794744] - Ibon Gurruchaga Sotés, Ana Nuño Alves, Sandra Vicente Arregui, Carmen Santander Lobera. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).
Current oncology (Toronto, Ont.).
2021 06; 28(4):2346-2350. doi:
10.3390/curroncol28040216. [PMID: 34202275] - Yasutomo Nakai, Ario Takeuchi, Takahiro Osawa, Takahiro Kojima, Tomohiko Hara, Mikio Sugimoto, Masatoshi Eto, Keita Minami, Kosuke Ueda, Michinobu Ozawa, Motohide Uemura, Yasuyuki Miyauchi, Kojiro Ohba, Akira Kashiwagi, Masaya Murakami, Tomokazu Sazuka, Hiroaki Yasumoto, Shuichi Morizane, Yoshihide Kawasaki, Daichi Morooka, Toru Shimazui, Yoshiaki Yamamoto, Hiroshi Nakagomi, Ryotaro Tomida, Yoichi M Ito, Sachiyo Murai, Hiroshi Kitamura, Hiroyuki Nishiyama, Nobuo Shinohara. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.
Journal of geriatric oncology.
2021 06; 12(5):834-837. doi:
10.1016/j.jgo.2020.12.012. [PMID: 33388281] - T K Choueiri, J Larkin, S Pal, R J Motzer, B I Rini, B Venugopal, B Alekseev, H Miyake, G Gravis, M A Bilen, S Hariharan, A Chudnovsky, K A Ching, X J Mu, M Mariani, P B Robbins, B Huang, A di Pietro, L Albiges. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
ESMO open.
2021 06; 6(3):100101. doi:
10.1016/j.esmoop.2021.100101. [PMID: 33901870] - Viral S Kansara, Leroy W Muya, Thomas A Ciulla. Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits.
Translational vision science & technology.
2021 06; 10(7):19. doi:
10.1167/tvst.10.7.19. [PMID: 34128964] - Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Kenichi Harada, Masato Fujisawa. Efficacy of axitinib rechallenge in metastatic renal cell carcinoma.
International journal of urology : official journal of the Japanese Urological Association.
2021 06; 28(6):702-703. doi:
10.1111/iju.14529. [PMID: 33719092] - D I Quinn, C F Ng, E Grande, T G Kwon, R Linke, J-L Lee, B Rosbrook, M N Thakur, M Eto, M Gross-Goupil. ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups.
ESMO open.
2021 06; 6(3):100105. doi:
10.1016/j.esmoop.2021.100105. [PMID: 33901868] - Arne Strauss, Marianne Schmid, Michael Rink, Michael Moran, Stephan Bernhardt, Marcus Hubbe, Lothar Bergmann, Katrin Schlack, Martin Boegemann. Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry.
Future oncology (London, England).
2021 Jun; 17(18):2325-2338. doi:
10.2217/fon-2020-1020. [PMID: 33724867] - Hiroki Hagimoto, Toshinari Yamazaki, Soki Kashima, Takayuki Yoshino, Takayuki Goto, Takeshi Sano, Atsuro Sawada, Shusuke Akamatsu, Takashi Kobayashi, Kenzo Nakano, Shintaro Yagi, Yui Matsuoka, Masakazu Fujimoto, Takaaki Kitamura, Osamu Ogawa. [Complete Remission of Metastatic Renal Cell Carcinoma with Invasion of the Duodenum and Pancreas after Treatment with Nivolumab Plus Ipilimumab Followed by Axitinib and Surgery : A Case Report].
Hinyokika kiyo. Acta urologica Japonica.
2021 May; 67(5):197-203. doi:
10.14989/actauroljap_67_5_197. [PMID: 34126663] - Thomas L Jenkins, Christopher M Aderman, Allen C Ho. REVERSIBLE RETINAL TOXICITY IN A PATIENT TAKING AXITINIB.
Retinal cases & brief reports.
2021 May; 15(3):239-242. doi:
10.1097/icb.0000000000000771. [PMID: 30015771] - Manuela Schmidinger, Irene Resch, Harun Fajkovic, Mesut Remzi, Shahrokh F Shariat, Jens Bedke. Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?.
Current opinion in urology.
2021 05; 31(3):270-275. doi:
10.1097/mou.0000000000000874. [PMID: 33742987] - Jindong Zhang, Shengjun Luo, Menghua Zeng, Delin Wang. Robot-assisted laparoscopic surgery combined with axitinib for renal cell carcinoma and inferior vena cava tumor thrombi in a patient with severe obesity and obstructive sleep apnea-hypopnea syndrome: A case report.
Asian journal of surgery.
2021 May; 44(5):781-782. doi:
10.1016/j.asjsur.2021.02.018. [PMID: 33814254] - Keita Tamura, Takahiro Osawa, Ario Takeuchi, Keita Minami, Yasutomo Nakai, Kosuke Ueda, Michinobu Ozawa, Motohide Uemura, Mikio Sugimoto, Kojiro Ohba, Toshihiro Suzuki, Satoshi Anai, Tetsuya Shindo, Naohisa Kusakabe, Motokiyo Komiyama, Ken Tanaka, Akira Yokomizo, Naoki Kohei, Nobuo Shinohara, Hideaki Miyake. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Japanese journal of clinical oncology.
2021 Apr; 51(5):810-818. doi:
10.1093/jjco/hyaa264. [PMID: 33479762] - Ana M Cardoso, Catarina M Morais, Frederico Pena, Tânia Marante, Pedro P Cunha, Amália S Jurado, Maria C Pedroso de Lima. Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib.
Human molecular genetics.
2021 04; 30(3-4):160-171. doi:
10.1093/hmg/ddab011. [PMID: 33438013] - Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C Brown, Chester Kao, Emily N Kinsey, Rajan T Gupta, Michael R Harrison, Andrew J Armstrong, Daniel J George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T Campbell. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Cancer medicine.
2021 04; 10(7):2341-2349. doi:
10.1002/cam4.3812. [PMID: 33650321] - Masahide Fukudo, Gaku Tamaki, Makoto Azumi, Hidehiro Kakizaki, Seiji Matsumoto, Yoshikazu Tasaki. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.
Investigational new drugs.
2021 04; 39(2):595-604. doi:
10.1007/s10637-020-01023-z. [PMID: 33098047] - Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Jamal C Tarazi, William Duggan, Rodolfo Perini, Mahgull Thakur, Kathrine C Fernandez, Toni K Choueiri. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
European journal of cancer (Oxford, England : 1990).
2021 03; 145(?):1-10. doi:
10.1016/j.ejca.2020.12.009. [PMID: 33412465] - Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H Giles, Milan Hora, Thomas B Lam, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
European urology.
2021 03; 79(3):339-342. doi:
10.1016/j.eururo.2020.12.005. [PMID: 33357997] - Christian Kollmannsberger, Toni K Choueiri, Daniel Y C Heng, Saby George, Fei Jie, Ruslan Croitoru, Srinivasu Poondru, John A Thompson. A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma.
The oncologist.
2021 03; 26(3):182-e361. doi:
10.1002/onco.13628. [PMID: 33289953] - T Anders Olsen, Dylan J Martini, Sean T Evans, Jamie M Goldman, Mehmet Asim Bilen. Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report.
Journal of medical case reports.
2021 Feb; 15(1):72. doi:
10.1186/s13256-020-02637-w. [PMID: 33602288] - Dong Ding, Huabin Hu, Yin Shi, Longjiang She, Linli Yao, Youwen Zhu, Shan Zeng, Liangfang Shen, Jin Huang. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
The oncologist.
2021 02; 26(2):e290-e297. doi:
10.1002/onco.13522. [PMID: 32918790] - Martina Spisarová, Bohuslav Melichar, Denisa Vitásková, Hana Študentová. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Future oncology (London, England).
2021 Jan; 17(3):241-254. doi:
10.2217/fon-2020-0079. [PMID: 33016119] - A A Stefaniak, E Wójcik, Ł Matusiak, J C Szepietowski. Axitinib-induced scrotal ulcers: a novel cutaneous adverse event.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2021 Jan; 35(1):e77-e78. doi:
10.1111/jdv.16821. [PMID: 32681664] - Yonghao Yang, Hao Huang, Tiepeng Li, Quanli Gao, Yongping Song, Zibing Wang. Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma.
Frontiers in immunology.
2021; 12(?):728750. doi:
10.3389/fimmu.2021.728750. [PMID: 34764951] - Shinya Takasaki, Yoshihide Kawasaki, Masafumi Kikuchi, Akihiro Ito, Hiroaki Yamaguchi, Nariyasu Mano. Clinical Importance of Plasma Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2021 ; 24(?):127-136. doi:
10.18433/jpps31816. [PMID: 34559626] - Annemarie Uhlig, Johannes Uhlig, Lutz Trojan, Michael Woike, Marianne Leitsmann, Arne Strauß. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
Future oncology (London, England).
2021 Jan; 17(1):45-56. doi:
10.2217/fon-2020-0900. [PMID: 33275038] - Tobias Engel Ayer Botrel, Márcia Datz Abadi, Laura Chabrol Haas, Cássia Rita Pereira da Veiga, Dominihemberg de Vasconcelos Ferreira, Denis Leonardo Jardim. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Journal of medical economics.
2021 Jan; 24(1):291-298. doi:
10.1080/13696998.2021.1883034. [PMID: 33538203] - Landon C Brown, Kunal Desai, Tian Zhang, Moshe C Ornstein. The Immunotherapy Landscape in Renal Cell Carcinoma.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
2020 Dec; 34(6):733-748. doi:
10.1007/s40259-020-00449-4. [PMID: 33048299] - Jiaxin Zhu, Tiantian Zhang, Ning Wan, Zhuoru Liang, Jiahao Li, Xudong Chen, Wenhua Liang, Jie Jiang. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
Immunotherapy.
2020 12; 12(17):1237-1246. doi:
10.2217/imt-2020-0034. [PMID: 32878521] - Thomas Powles, Elizabeth R Plimack, Denis Soulières, Tom Waddell, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Frédéric Pouliot, Bohuslav Melichar, Ihor Vynnychenko, Sergio J Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Lina Yin, Mei Chen, L Rhoda Molife, Michael B Atkins, Brian I Rini. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
The Lancet. Oncology.
2020 12; 21(12):1563-1573. doi:
10.1016/s1470-2045(20)30436-8. [PMID: 33284113] - Maryam Soleimani, Lucia Nappi, Christian Kollmannsberger. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
Future oncology (London, England).
2020 Dec; 16(36):3021-3034. doi:
10.2217/fon-2020-0586. [PMID: 32856478] - Kurt Miller, Lothar Bergmann, Christian Doehn, Viktor Grünwald, Jürgen E Gschwend, Philipp Ivanyi, Ulrich Keilholz, Markus A Kuczyk. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
Aktuelle Urologie.
2020 Dec; 51(6):572-581. doi:
10.1055/a-1252-1780. [PMID: 33027832] - Giuseppe Procopio, Federico Nichetti, Elena Verzoni. Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma.
The Lancet. Oncology.
2020 12; 21(12):1538-1539. doi:
10.1016/s1470-2045(20)30482-4. [PMID: 33284112] - Kazuyuki Numakura, Mizuki Kobayashi, Yumina Muto, Yuya Sekine, Makoto Takahashi, Soki Kashima, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara, Mitsuru Saito, Shintaro Narita, Hiroshi Nanjyo, Tomonori Habuchi. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
Scientific reports.
2020 11; 10(1):20089. doi:
10.1038/s41598-020-77135-6. [PMID: 33208816] - David Killock. Biomarkers 101 - personalizing therapy for RCC.
Nature reviews. Clinical oncology.
2020 11; 17(11):653. doi:
10.1038/s41571-020-00434-4. [PMID: 32948859] - Jincheng Zhong, Weijin Lu, Jiayan Zhang, Maohua Huang, Wenyu Lyu, Geni Ye, Lijuan Deng, Minfeng Chen, Nan Yao, Yong Li, Guanping Liu, Yunfei Liang, Jingwen Fu, Dongmei Zhang, Wencai Ye. Notoginsenoside R1 activates the Ang2/Tie2 pathway to promote angiogenesis.
Phytomedicine : international journal of phytotherapy and phytopharmacology.
2020 Nov; 78(?):153302. doi:
10.1016/j.phymed.2020.153302. [PMID: 32823242] - Robert J Motzer, Paul B Robbins, Thomas Powles, Laurence Albiges, John B Haanen, James Larkin, Xinmeng Jasmine Mu, Keith A Ching, Motohide Uemura, Sumanta K Pal, Boris Alekseev, Gwenaelle Gravis, Matthew T Campbell, Konstantin Penkov, Jae Lyun Lee, Subramanian Hariharan, Xiao Wang, Weidong Zhang, Jing Wang, Aleksander Chudnovsky, Alessandra di Pietro, Amber C Donahue, Toni K Choueiri. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Nature medicine.
2020 11; 26(11):1733-1741. doi:
10.1038/s41591-020-1044-8. [PMID: 32895571] - Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, David F McDermott, Igor Puzanov, Mayer N Fishman, Daniel C Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C Fernandez, Jamal C Tarazi, Saby George, Michael B Atkins. Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 11; 26(21):5598-5608. doi:
10.1158/1078-0432.ccr-20-1408. [PMID: 32816890] - Fabian Hofmann, Eu Chang Hwang, Thomas Bl Lam, Axel Bex, Yuhong Yuan, Lorenzo So Marconi, Börje Ljungberg. Targeted therapy for metastatic renal cell carcinoma.
The Cochrane database of systematic reviews.
2020 10; 10(?):CD012796. doi:
10.1002/14651858.cd012796.pub2. [PMID: 33058158] - F Spada, S Pellicori, G Zampino, L Funicelli, L Gervaso, A Laffi, M Rubino, R Garcia-Carbonero, N Fazio. SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view.
Endocrine.
2020 10; 70(1):6-10. doi:
10.1007/s12020-020-02419-w. [PMID: 32681385] - Ozgur Tanriverdi, Sedef Ates, Kerim K Sandal, Selcuk Uylas, Islam C Bosna, Ali Alkan. Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2020 Oct; 26(7):1765-1768. doi:
10.1177/1078155220909422. [PMID: 32164490] - Tina R Watson, Xin Gao, Kerry L Reynolds, Chung Yin Kong. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
JAMA network open.
2020 10; 3(10):e2016144. doi:
10.1001/jamanetworkopen.2020.16144. [PMID: 33052401] - Lajos Géczi, György Bodoky, György Rokszin, Ibolya Fábián, László Torday. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Pathology oncology research : POR.
2020 Oct; 26(4):2201-2207. doi:
10.1007/s12253-020-00809-z. [PMID: 32291570] - Kotaro Suzuki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
International journal of clinical oncology.
2020 Sep; 25(9):1678-1686. doi:
10.1007/s10147-020-01708-8. [PMID: 32488547] - Marina Deuker, Felix K H Chun, Pierre I Karakiewicz. Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure.
Current opinion in supportive and palliative care.
2020 09; 14(3):276-285. doi:
10.1097/spc.0000000000000519. [PMID: 32769619] - Viktor Grünwald, Martin H Voss, Brian I Rini, Thomas Powles, Laurence Albiges, Rachel H Giles, Eric Jonasch. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
British journal of cancer.
2020 09; 123(6):898-904. doi:
10.1038/s41416-020-0949-9. [PMID: 32587360] - NULL. Title Not Available.
Der Urologe. Ausg. A.
2020 09; 59(9):1157-1159. doi:
10.1007/s00120-020-01298-3. [PMID: 32865647] - Arielle G Bensimon, Yichen Zhong, Umang Swami, Allison Briggs, Joshua Young, Yuan Feng, Yan Song, James Signorovitch, Oluwakayode Adejoro, Abhiroop Chakravarty, Mei Chen, Rodolfo F Perini, Daniel M Geynisman. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Current medical research and opinion.
2020 09; 36(9):1507-1517. doi:
10.1080/03007995.2020.1799771. [PMID: 32697113] - Guanghui Cao, Xiaoqiang Wu, Zhiwei Wang, Xiangyong Tian, Chan Zhang, Xuan Wu, Haotian Zhang, Gaopeng Jing, Tianzhong Yan. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
BMJ open.
2020 08; 10(8):e034626. doi:
10.1136/bmjopen-2019-034626. [PMID: 32859659] - Ángeles López-López, Joanna Godzien, Beatriz Soldevilla, Ana Gradillas, Ángeles López-Gonzálvez, Alberto Lens-Pardo, Anna La Salvia, María Del Carmen Riesco-Martínez, Rocío García-Carbonero, Coral Barbas. Oxidized lipids in the metabolic profiling of neuroendocrine tumors - Analytical challenges and biological implications.
Journal of chromatography. A.
2020 Aug; 1625(?):461233. doi:
10.1016/j.chroma.2020.461233. [PMID: 32709312] - Gianluca Perego, Paolo Barzaghi, Ivano Vavassori, Fausto Petrelli. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Medical oncology (Northwood, London, England).
2020 Aug; 37(9):81. doi:
10.1007/s12032-020-01408-3. [PMID: 32767163] - Yuqing Li, Yanyun Shen, Zhidong Zhu, Hui Wen, Chenchen Feng. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
Cancer medicine.
2020 08; 9(16):6020-6029. doi:
10.1002/cam4.3281. [PMID: 32628820] - Luca Moscetti, Paula Hennik, Bjorg Bolstad, Jorge Camarero, Filip Josephson, Daniela Melchiorri, Maja Sommerfelt Grønvold, Jan Sjoberg, Mihaela Botezatu, Jorn Mulder, Didier Meulendijks, Ana Trullas Jimeno, Nikolaos Zafiropoulos, Jonas Bergh, Harald Enzmann, Francesco Pignatti. Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects.
ESMO open.
2020 08; 5(4):. doi:
10.1136/esmoopen-2020-000856. [PMID: 32847837]